The Genio system is a battery-free hypoglossal nerve stimulator developed by Nyxoah. It received FDA clearance in March 2024 for adults with moderate-to-severe obstructive sleep apnea who cannot tolerate CPAP therapy. The device works by stimulating the hypoglossal nerve to keep the airway open during sleep.
Clinical results from the DREAM trial are notable. The trial reported a 53% median reduction in AHI scores, a 62% responder rate, and a 91% patient satisfaction rating. These figures place Genio among the more effective surgical alternatives to CPAP. The bilateral stimulation design distinguishes it from older implantable options on the market.
Cost is a significant factor for most patients considering this treatment. The Genio system runs between $15,000 and $30,000 USD, and insurance coverage remains unavailable as of 2025. Compared to the Inspire device, which received FDA approval in 2014, Genio’s battery-free design eliminates the need for future battery replacement surgery.
What Is Genio Sleep Apnea Therapy?
The Genio system is a battery-free hypoglossal nerve stimulator developed by Nyxoah, a Belgian medical device company, designed to treat moderate-to-severe obstructive sleep apnea in adults who can’t use or have failed CPAP therapy. It targets OSA at its anatomical source by stimulating the nerve that controls tongue movement during sleep.
The Genio system received FDA clearance in March 2024. That clearance positions it as one of the newest implantable alternatives for patients who’ve exhausted CPAP as a viable long-term solution.
The system has two parts: a small implant placed under the chin near the base of the tongue, and an external disposable adhesive patch worn on the chin each night. The patch powers the implant wirelessly, and no internal battery is required at any point during the device’s operational lifetime.
How Does the Genio System Work?
The Genio system works by stimulating the hypoglossal nerve with mild electrical pulses during sleep, preventing the tongue from collapsing backward and keeping the upper airway open to reduce obstructive apnea events throughout the night. The stimulation kicks in automatically once the external patch is applied and activated.
Each night, the user applies a disposable adhesive patch to the chin before bed and activates the device through a smartphone app. The patch transfers power to the implant wirelessly, then it’s removed and discarded each morning as part of the daily routine.
Here’s the key engineering difference: the patch transfers radiofrequency energy wirelessly to the battery-free implant during each sleep session. No internal battery exists within the implant, so patients are never subject to the surgical battery replacement procedures required by competing hypoglossal nerve stimulation devices.
Nightly Genio Use – Step by Step:
- Apply the disposable adhesive patch to the chin before bed
- Activate the device through the companion smartphone app
- Sleep while the patch wirelessly powers the implant via radiofrequency energy
- Remove and discard the patch each morning
What Are the Components of the Genio Device?
The Genio device consists of three components: a battery-free implant placed surgically under the chin, a disposable external adhesive patch worn nightly on the chin, and a companion smartphone app used to activate and control the system before sleep. Each component serves a distinct and non-redundant role in the therapy.
The implant is a small, battery-free device placed under the chin near the base of the tongue during a surgical procedure. And here’s what makes that matter: because there’s no internal battery, the implant is designed to remain in place indefinitely without ever requiring replacement surgery.
The external adhesive patch is a single-use component worn on the chin during sleep that wirelessly powers the implant via radiofrequency energy. It’s discarded each morning, making it the only consumable element of the two-part Genio system.
A companion smartphone app lets the patient activate and control the device each night before sleep. Some patients report an initial learning curve with the app, though most users adapt to the activation routine within the first few weeks of nightly use.
Genio System Components:
| Component | Type | Role |
|---|---|---|
| Battery-free implant | Permanent surgical implant | Receives wireless power and stimulates the hypoglossal nerve |
| Disposable adhesive patch | Single-use consumable | Worn on the chin nightly to wirelessly power the implant |
| Smartphone app | Software companion | Activates and controls the system before each sleep session |
Is the Genio System FDA Approved?
Yes. The Genio system received FDA clearance in March 2024 for treating moderate-to-severe obstructive sleep apnea in adults who are unable to use or have failed CPAP therapy, making it one of the newest implantable OSA treatments on the US market. FDA clearance confirms the device met the agency’s standards for safety and efficacy.
That clearance was supported by the DREAM trial, a pivotal multi-site study enrolling 115 patients across 11 clinical centers. The trial demonstrated statistically significant reductions in AHI, ODI, and daytime sleepiness, alongside a 91% patient satisfaction rate that regulators accepted as evidence of real-world acceptability.
What Does the Clinical Evidence Say About Genio?
The clinical evidence shows Genio produces a 53% median AHI reduction and a 62% responder rate in the DREAM trial, alongside a 48% ODI reduction and a 91% patient satisfaction rate, confirming both objective efficacy and strong real-world acceptability among treated patients.
The DREAM trial demonstrated a 53% median reduction in the apnea-hypopnea index and a 62% responder rate. Responders achieved both an AHI reduction of at least 50% and a final AHI below 20 events per hour. These figures place Genio’s efficacy within the accepted range for hypoglossal nerve stimulation therapies.
And here is the best part: beyond AHI, the trial showed a 48% reduction in the oxygen desaturation index, and 91% of patients reported being satisfied or very satisfied. Both outcomes reflect a device that performs consistently across objective sleep metrics and subjective patient experience alike.
Clinical data from the DREAM trial also captured improvements in daytime sleepiness, a core patient-reported outcome in OSA care. So the benefits aren’t only improved polysomnography readings. They show up in waking life too.
DREAM Trial Key Outcomes:
| Metric | Result |
|---|---|
| Median AHI reduction | 53% |
| Oxygen desaturation index (ODI) reduction | 48% |
| Responder rate (AHI reduction 50%+ and final AHI below 20) | 62% |
| Patient satisfaction rate | 91% |
What Were the DREAM Trial Results for Genio?
The DREAM trial enrolled 115 patients across 11 clinical centers and recorded a 53% median AHI reduction, a 48% ODI reduction, a 62% responder rate, and a 91% patient satisfaction rate, forming the complete evidentiary basis for Genio’s FDA clearance in March 2024.
The DREAM trial was the pivotal study supporting Genio’s FDA clearance. Its multi-site design, spanning 115 patients across 11 centers, produced a dataset that regulatory reviewers accepted as sufficient evidence of the device’s safety and efficacy profile.
62% of enrolled patients met the formal responder definition. That means an AHI reduction of 50% or more combined with a post-treatment AHI under 20 events per hour. This responder threshold mirrors the benchmarks used in other hypoglossal nerve stimulation trials, allowing for cross-device comparison.
The trial recorded a 53% median AHI reduction and a 48% ODI reduction across the patient cohort. Both metrics are standard polysomnography measures of sleep apnea severity, and these reductions indicate a clinically meaningful decrease in breathing interruptions and oxygen dips during sleep.
How Effective Is Genio for Sleep Apnea?
Genio is effective for sleep apnea, producing a 53% median AHI reduction and a 62% responder rate in the DREAM trial, with 91% patient satisfaction, placing its performance broadly in line with other hypoglossal nerve stimulators for CPAP-intolerant adults. These results come from a multi-site pivotal trial accepted by the FDA.
91% of patients in the DREAM trial reported being satisfied or very satisfied with the Genio system. This satisfaction rate indicates the device’s real-world tolerability matches its clinical performance metrics. That’s a combination that isn’t always observed in implantable medical device studies.
Unlike Inspire, which stimulates one side of the tongue, Genio delivers bilateral stimulation to both sides simultaneously. This design difference may produce more symmetrical airway opening during sleep, though head-to-head comparative clinical trials between the two devices aren’t yet available.
Does the Genio Device Actually Work?
Yes. In the DREAM trial, 62% of patients met the formal responder threshold of an AHI reduction of 50% or more and a final AHI below 20 events per hour, confirming the device produces measurable, clinically significant reductions in obstructive sleep apnea severity for the majority of eligible users.
Beyond the responder rate, the DREAM trial showed a 53% median AHI reduction and a 48% ODI drop across the enrolled cohort. Both are objective polysomnography metrics that confirm the device is mechanically effective at reducing airway obstruction events throughout the sleep period.
Patients also reported improvements in daytime sleepiness alongside the objective AHI reductions. So what does that mean for you? Genio’s nightly hypoglossal nerve stimulation translates into better daytime alertness and energy for most users, not only improved sleep-study numbers recorded in a laboratory setting.
What Do Patients Say About Genio?
Patients report improved sleep quality, reduced snoring, increased daytime energy, and the freedom from wearing a CPAP mask each night as the most frequently cited benefits of Genio therapy, with 91% of DREAM trial participants reporting overall satisfaction with the system. The absence of a mask is consistently highlighted as a primary quality-of-life gain.
Some users experience discomfort from the chin patch adhesive during nightly application and morning removal. Others note an initial learning curve when first using the smartphone app to activate the device, though the majority of patients adapt to both elements within the first few weeks of use.
91% of DREAM trial participants reported being satisfied or very satisfied with the Genio system. This figure reflects strong acceptance of both the implant procedure and the nightly patch-based routine among real patients living with the device outside of a controlled clinical setting.
Most Frequently Cited Patient Benefits:
- Improved sleep quality and fewer nighttime awakenings
- Reduced or eliminated snoring
- Increased daytime energy and alertness
- Freedom from wearing a CPAP mask each night
- No bedside machine, hose, or nightly equipment setup
What Are the Side Effects of Genio?
The side effects of Genio include temporary tongue weakness, tongue discomfort, difficulty swallowing, wound complications at the implant site, and device discomfort under the chin, with the majority of these adverse effects characterized as mild-to-moderate in severity and resolving over time. No pattern of serious or life-threatening adverse events was reported in DREAM trial data.
The good news? Clinical trial data characterize most Genio-related adverse events as mild-to-moderate and temporary. These effects are not permanent and typically diminish during the post-surgical healing period and the initial device adaptation phase that follows implantation.
Reported Side Effects:
- Temporary tongue weakness
- Tongue discomfort or soreness
- Difficulty swallowing (dysphagia)
- Wound complications at the implant site
- Device discomfort under the chin
- Skin irritation from nightly adhesive patch use
Is Genio Safe for Sleep Apnea?
Yes. The FDA cleared Genio in March 2024 after reviewing DREAM trial safety data from 115 patients across 11 centers, concluding that the device’s benefit-risk profile is acceptable for adults with moderate-to-severe OSA who have failed CPAP therapy. No serious or life-threatening adverse events were reported in the trial dataset.
Side effects observed in clinical trials, including tongue weakness, dysphagia, and implant site discomfort, were predominantly mild-to-moderate and temporary in nature. The DREAM trial data showed no pattern of serious adverse events, supporting the FDA’s determination that the device’s safety profile is acceptable for the indicated population.
And here is the kicker: because the Genio implant contains no internal battery, patients are never exposed to the risks associated with battery replacement surgery. Competing devices such as Inspire require that procedure approximately every 10 years. Genio’s battery-free architecture eliminates it entirely.
Who Should Not Use Genio?
Patients who should not use Genio include those with an AHI outside the 15-65 events/hour range, a BMI above 35, age under 22, or complete concentric palatal collapse confirmed on drug-induced sleep endoscopy, as each condition either falls outside the approved indication or predicts poor therapeutic response.
Patients with an AHI below 15 or above 65 events per hour are excluded from Genio therapy. These thresholds reflect the population studied in the DREAM trial and the anatomical conditions under which the device performs reliably. Candidates whose disease severity falls outside this window aren’t considered appropriate implant recipients.
Complete concentric collapse of the palate, identified during drug-induced sleep endoscopy, is a firm anatomical contraindication. This airway collapse pattern indicates hypoglossal nerve stimulation is unlikely to adequately open the airway during sleep. Any candidate showing this pattern on endoscopy is disqualified before surgery proceeds.
The Genio system is approved for adults aged 22 and older. Use in younger patients falls outside the cleared indication and hasn’t been evaluated in the clinical trials supporting FDA clearance. Surgeons operating within approved labeling can’t offer the device to patients below this age threshold.
Genio Contraindications:
- AHI below 15 or above 65 events per hour
- BMI above 35
- Age under 22
- Complete concentric palatal collapse on drug-induced sleep endoscopy
Are You Eligible for Genio Therapy?
Eligible candidates are adults aged 22 or older with moderate-to-severe OSA (AHI 15-65 events/hour), a BMI of 35 or below, documented CPAP failure or intolerance, and no complete concentric palatal collapse on drug-induced sleep endoscopy, the profile validated in the DREAM trial.
The core patient profile mirrors the population enrolled in the DREAM trial. Eligible adults must present with moderate-to-severe OSA, a BMI at or below 35, and a history of failing or being unable to tolerate CPAP therapy. Meeting all three criteria is necessary before further pre-operative evaluation is scheduled.
Drug-induced sleep endoscopy is a required step before implantation for every candidate. This procedure lets the surgeon directly assess airway collapse patterns and confirm the absence of complete concentric palatal collapse. Candidates with that specific collapse pattern are disqualified regardless of how well they meet the other eligibility criteria.
What Conditions Qualify You for Genio?
Qualifying conditions for Genio include moderate-to-severe OSA with an AHI between 15 and 65 events per hour, a BMI of 35 or below, and documented failure or intolerance to CPAP therapy, the three core criteria established through the DREAM trial and required for FDA-cleared use.
Genio is indicated specifically for moderate-to-severe OSA, defined as an AHI between 15 and 65 events per hour. Patients with very mild OSA below 15 or extremely severe disease above 65 fall outside the approved indication. The reason is simple: the trial population was built around this range because it reflects the severity level where hypoglossal nerve stimulation produces clinically meaningful outcomes.
A BMI at or below 35 is a firm eligibility requirement. Higher BMI values are associated with increased soft tissue around the airway and anatomical factors that reduce the effectiveness of hypoglossal nerve stimulation. Patients above this threshold are excluded because the device is less likely to produce adequate airway opening under those anatomical conditions.
CPAP failure or intolerance is a prerequisite, not a disqualifying factor. This requirement positions Genio as a second-line surgical intervention for those for whom the gold-standard non-surgical treatment isn’t a viable long-term option. Candidates who remain successfully treated by CPAP aren’t considered appropriate Genio recipients.
Core Eligibility Criteria:
| Criterion | Required Value |
|---|---|
| Age | 22 years or older |
| OSA severity (AHI) | 15 to 65 events per hour |
| BMI | 35 or below |
| CPAP history | Documented failure or intolerance |
| Palatal collapse pattern | No complete concentric palatal collapse on DISE |
Is Genio an Option If CPAP Has Failed?
Yes. Genio is explicitly FDA-cleared for adults who can’t use or have failed CPAP therapy, making CPAP failure a qualifying condition rather than a barrier, as the device is designed precisely for this patient population rather than as a first-line treatment.
CPAP failure is a core qualifying criterion, not an obstacle to candidacy. The Genio system was developed for patients who can’t achieve or maintain adherence to continuous positive airway pressure therapy. Physicians evaluating candidates specifically look for documented CPAP failure or intolerance as part of the pre-implant screening process.
And this is where it gets interesting: Genio eliminates the primary reasons patients abandon CPAP. No mask, hose, or bedside machine. Patients apply only a small external chin patch each night, then sleep without any equipment attached to the face or body, addressing the tolerance problems that made CPAP unworkable for them.
Reasons Patients Abandon CPAP That Genio Addresses:
- Mask discomfort and pressure sores
- Claustrophobia from face-covering equipment
- Noise from the CPAP machine disrupting sleep or partners
- Travel inconvenience of carrying bulky equipment
- Difficulty maintaining consistent nightly adherence
Genio vs Inspire: Which Is Better for Sleep Apnea?
Neither device is universally superior; Genio offers a battery-free implant with bilateral stimulation and no future replacement surgery, while Inspire carries a decade of real-world outcomes data since its 2014 FDA approval, making the better choice depend on each patient’s priorities and clinical profile.
Genio’s implant is battery-free, powered nightly by an external disposable patch via radiofrequency energy. Inspire requires an internal battery that must be surgically replaced approximately every 10 years. Over a multi-decade treatment horizon, that procedural difference represents both a cost consideration and an additional surgical exposure for Inspire patients.
Genio delivers bilateral hypoglossal nerve stimulation, activating musculature on both sides of the tongue. Inspire uses unilateral stimulation and a three-component system including an implant, breathing sensor, and remote. The clinical significance of bilateral versus unilateral stimulation on airway opening remains under active study.
Here’s the honest trade-off: Inspire has been FDA-approved since 2014, accumulating over a decade of real-world outcomes data. Genio received FDA clearance only in March 2024, meaning long-term durability data beyond the DREAM trial is still limited. Patients who prioritize an established track record will find the evidence base for Inspire substantially larger at this time.
Genio vs Inspire – Side-by-Side Comparison:
| Feature | Genio | Inspire |
|---|---|---|
| FDA clearance/approval year | 2024 | 2014 |
| Internal battery | None (battery-free) | Yes (requires replacement every 10 years) |
| Stimulation type | Bilateral | Unilateral |
| Number of components | 2 (implant + external patch) | 3 (implant + breathing sensor + remote) |
| Long-term real-world data | Limited (post-2024) | Extensive (10+ years) |
| Battery replacement surgery required | No | Yes (every 10 years) |
How Does Genio Stand Out From Other Neurostimulation Treatments?
Genio stands out through its battery-free implant design, bilateral hypoglossal nerve stimulation targeting both sides of the tongue simultaneously, and a simplified two-component architecture, features no other FDA-cleared neurostimulation device for sleep apnea currently combines in a single system.
Genio’s most distinctive engineering feature is its battery-free implant, powered externally each night through the disposable chin patch. No other FDA-cleared hypoglossal nerve stimulator shares this design. The absence of an internal power source eliminates the need for repeat surgery to replace an aging battery, a procedural requirement that affects competing implant systems.
Genio stimulates the hypoglossal nerve bilaterally, activating musculature on both sides of the tongue simultaneously. Competing devices such as Inspire target only one side of the nerve. This design difference may affect how completely and symmetrically the tongue is protruded during sleep, though the full clinical implications of bilateral versus unilateral stimulation are still being evaluated.
Think of it this way: Genio uses only two components, a subcutaneous implant and an external patch, while Inspire’s architecture requires three implanted or worn components. Fewer implanted components may reduce surgical complexity, shorten the procedure, and lower the number of potential hardware failure points over the device’s lifespan.
How Much Does Genio Cost?
The Genio system costs approximately $15,000 to $30,000 USD out of pocket in the United States, with variation driven by surgeon fees, facility costs, pre-operative drug-induced sleep endoscopy, and geographic market differences, and most US insurance plans have not yet established coverage as of 2025.
The $15,000-$30,000 range reflects real variation across implanting centers. Surgeon fees, hospital or surgical facility charges, anesthesia, and pre-operative evaluation each contribute to the final cost. Patients in major metropolitan markets or academic medical centers may face higher fees than those in lower-cost regions.
But here’s a longer-term consideration: because Genio’s implant contains no battery, patients avoid the cost and surgical risk of battery replacement required by competing devices like Inspire approximately every 10 years. Over two or three decades, the savings from avoiding one or more replacement procedures may meaningfully offset Genio’s higher initial price point.
Factors That Affect Genio Total Cost:
- Surgeon fees at the implanting center
- Hospital or surgical facility charges
- Anesthesia costs
- Pre-operative drug-induced sleep endoscopy
- Geographic market and regional pricing differences
- Ongoing nightly disposable patch expense
Is Genio Covered by Insurance?
No. Genio is not yet widely covered by US health insurance plans as of 2024-2025; its March 2024 FDA clearance means most payers haven’t established coverage policies, leaving the majority of patients responsible for the full $15,000-$30,000 out-of-pocket cost.
The bad news? FDA clearance in March 2024 was recent enough that most US insurers haven’t completed coverage determinations for the Genio system. Payers typically require time to review clinical evidence, conduct technology assessments, and issue formal coverage policies after a device enters the market. Until those policies exist, the procedure is generally classified as non-covered by commercial plans and Medicare.
Genio has been available in Europe and Australia longer than in the United States, and reimbursement pathways in those markets may differ from the current US situation. US patients should contact their insurer directly to request prior authorization and monitor for emerging coverage decisions. Patients willing to pursue appeals or work with their surgical team on documentation may have options worth exploring.
Where Can You Get Genio for Sleep Apnea?
Genio is available at select certified implanting centers in Europe, Australia, and the United States, with the US network still expanding following the March 2024 FDA clearance, and patients can locate qualified surgeons through resources provided by Nyxoah, the device manufacturer.
Because FDA clearance was granted only in March 2024, the network of US-based implanting surgeons is still expanding and not yet as broad as that for longer-established devices such as Inspire. Patients in smaller US markets may need to travel to a regional academic or specialty sleep surgery center.
Patients seeking Genio should look for a qualified ENT or sleep surgeon trained specifically in the Genio implantation procedure. Nyxoah, the device manufacturer, maintains resources to help patients locate certified implanting centers in their region. Contacting Nyxoah directly or asking a sleep medicine physician for a referral is the recommended starting point.
Is Genio Worth It for Sleep Apnea?
For the right candidate, Genio is worth considering; CPAP-intolerant adults who meet eligibility criteria gain a clinically validated alternative with a 62% responder rate, 91% patient satisfaction, and no future battery replacement surgery, though the $15,000-$30,000 cost and limited insurance coverage remain significant barriers for most patients.
For patients who’ve genuinely failed CPAP and meet all eligibility criteria, Genio offers a clinically validated path to durable nightly symptom relief. The DREAM trial reported a 62% responder rate and 91% patient satisfaction. For these patients, the upfront cost may be justified by sustained relief without a mask.
But prospective patients must weigh several factors before committing. The $15,000-$30,000 upfront cost, limited US insurance coverage as of 2025, and the device’s short post-FDA real-world track record are material concerns. Patients should evaluate those drawbacks against the benefit of eliminating CPAP and avoiding future battery replacement surgeries before a decision is reached.
What Are the Pros and Cons of the Genio System?
The Genio system’s primary advantages include a battery-free implant, bilateral tongue stimulation, simplified two-component design, no CPAP mask, 91% patient satisfaction, and 53% median AHI reduction in trials, while its drawbacks include high cost, limited insurance coverage, a short US track record, nightly patch expense, and strict eligibility criteria.
Key Advantages:
- No internal battery and no future battery replacement surgery
- Bilateral hypoglossal nerve stimulation activating both sides of the tongue
- Simplified two-component system reducing implanted hardware
- No CPAP mask, hose, or bedside machine required nightly
- 91% patient satisfaction rate reported in the DREAM trial
- 53% median AHI reduction demonstrated in clinical evidence
- FDA cleared as of March 2024
Key Drawbacks:
- High out-of-pocket cost of $15,000-$30,000 in the United States
- Limited US insurance coverage as of 2025
- Short post-clearance real-world track record compared to Inspire
- Ongoing nightly disposable patch expense
- Possible adhesive skin discomfort with regular patch use
The device carries strict eligibility requirements that exclude a large proportion of OSA patients. Candidates must present with an AHI between 15 and 65, a BMI of 35 or below, documented CPAP failure, and confirmed absence of complete concentric palatal collapse on sleep endoscopy. Side effects including tongue weakness and dysphagia, though reported as mostly temporary in trial data, are an additional consideration patients and clinicians must discuss before proceeding.